Adamas Pharmaceuticals EBIT

Adamas Pharmaceuticals (ADMS) currently reports a EBIT of $-39M as of September 2021. That compares with $-49M in the prior-year period — up 19.4% year over year. That is below the Healthcare sector average of $110B. Use the charts on this page to explore Adamas Pharmaceuticals's EBIT history and peer comparisons.

Adamas Pharmaceuticals's EBIT increased from $-49M to $-39M — a 19.4% year-over-year increase (period ending September 2021). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Adamas Pharmaceuticals's EBIT of $-39M is lower than the Healthcare sector average of $110B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Adamas Pharmaceuticals reported $-39M in EBIT as of September 2021. That compares with $-49M in the prior-year period — up 19.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-39M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for Adamas Pharmaceuticals, and consider following ADMS for alerts when major investors trade the stock.